/
APUS
$0.93+$0.03 (+2.78%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$13.6M
15M shares
52-week range
$0.79 – $40.31
0% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
XASE
CS
Borrow rate
14.42%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-21.07
Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
www.apimedsus.com- Employees
- 7
- IPO / List date
- May 9, 2025
- HQ
- MATAWAN, NJ
Held by traders on TradeandTell
No one on the platform currently holds APUS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 27,893 | $49.7K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-03-26 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded APUS yet.
